Effectiveness and Acceptability of SDF Compared to ART for the Management of Early Childhood Caries
Launched by UNIVERSIDAD DE LA FRONTERA · Jan 15, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different treatments for young children with early childhood caries, which is a type of tooth decay. The researchers want to find out if Silver Diamine Fluoride (SDF), a liquid that helps stop cavities, is more accepted and effective than Atraumatic Restorative Treatment (ART), a method where cavities are filled without drilling. The study will include children aged 2 to 5 years who have at least one cavity that has not affected the nerve of the tooth. Parents will need to provide consent for their child’s participation.
If eligible, children will receive one of the two treatments, and their parents will be asked to fill out surveys about their child’s oral health before and after treatment. The study will involve follow-up visits at 6 and 12 months to see how well the treatments worked and how satisfied families are with the care provided. This trial is important because it aims to improve how we manage tooth decay in young children, making dental care more effective and acceptable for families in the community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children belonging to INTEGRA or JUNJI kindergarten, from 2 years up to 5 years and 11 months with informed consent signed by parents and assent from the child.
- • Children with at least one active cavitated caries lesion, extended in dentin with no signs of pulp involvement and diagnosed with ICDAS code 5.
- Exclusion Criteria:
- • Children with underlying systemic disease or disability
- • Children with known allergies to dental materials used
- • Children with transitory residence
- • Children with severe alterations of the dental estructure
About Universidad De La Frontera
Universidad de la Frontera is a distinguished academic institution dedicated to advancing health sciences through innovative research and clinical trials. Located in Chile, the university fosters a collaborative environment that integrates multidisciplinary expertise to address pressing health challenges. With a commitment to ethical standards and patient safety, Universidad de la Frontera actively engages in clinical research aimed at improving healthcare outcomes and contributing valuable insights to the global medical community. Its robust research infrastructure and emphasis on education position it as a leader in the field of clinical trials and translational medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Temuco, , Chile
Temuco, La Araucanía, Chile
Patients applied
Trial Officials
Patricia Muñoz, Master
Study Director
Universidad de La Frontera
Patricia Pineda, Master
Study Chair
Universidad de La Frontera
Carlos Zaror, Doctor
Study Chair
Universidad de La Frontera
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported